France’s HRA Pharma SA is poised to establish a solid footing in the US consumer health market by acquiring from Germany’s Merz GmbH & Co. KGaA the popular Mederma OTC dermatology brand.
Through the deal - slated to close within the second quarter - HRA will gain the global rights to the Mederma brand, which includes products across the scar-care, stretch marks and skin-care categories, as well as the rights to the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?